245 related articles for article (PubMed ID: 2908050)
1. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum.
Boyson SJ; McGonigle P; Luthin GR; Wolfe BB; Molinoff PB
J Pharmacol Exp Ther; 1988 Mar; 244(3):987-93. PubMed ID: 2908050
[TBL] [Abstract][Full Text] [Related]
2. Phenytoin potentiation of neuroleptic-induced dyskinesias.
Sethi KD; Hitri A; Diamond BI
Mov Disord; 1990; 5(4):325-7. PubMed ID: 2147979
[TBL] [Abstract][Full Text] [Related]
3. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain.
O'Dell SJ; La Hoste GJ; Widmark CB; Shapiro RM; Potkin SG; Marshall JF
Synapse; 1990; 6(2):146-53. PubMed ID: 2237777
[TBL] [Abstract][Full Text] [Related]
4. Classification of neuroleptics: implications for tardive dyskinesia.
Christensen AV
Pol J Pharmacol Pharm; 1985; 37(3):295-309. PubMed ID: 2866499
[TBL] [Abstract][Full Text] [Related]
5. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
6. Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission.
Calabresi P; De Murtas M; Mercuri NB; Bernardi G
Ann Neurol; 1992 Apr; 31(4):366-73. PubMed ID: 1350190
[TBL] [Abstract][Full Text] [Related]
7. Neuroleptic drugs and their action on different neuronal pathways.
Ungerstedt U; Herrera-Marschitz M; Forster C
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
[TBL] [Abstract][Full Text] [Related]
8. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
9. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.
Coffin VL; Latranyi MB; Chipkin RE
J Pharmacol Exp Ther; 1989 Jun; 249(3):769-74. PubMed ID: 2567351
[TBL] [Abstract][Full Text] [Related]
10. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
11. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
[TBL] [Abstract][Full Text] [Related]
12. Regional selectivity of neuroleptic drugs: an argument for site specificity.
Borison RL; Diamond BI
Brain Res Bull; 1983 Aug; 11(2):215-8. PubMed ID: 6138135
[TBL] [Abstract][Full Text] [Related]
13. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats.
Jenner P; Kerwin R; Rupniak NM; Murugaiah K; Hall MD; Fleminger S; Marsden CD
J Neural Transm Suppl; 1983; 18():205-12. PubMed ID: 6135741
[TBL] [Abstract][Full Text] [Related]
14. The pathophysiology of tardive dyskinesia.
Klawans HL; Carvey P; Tanner CM; Goetz CG
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
[TBL] [Abstract][Full Text] [Related]
15. Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects.
Sayers AC; Bürki HR; Ruch W; Asper H
Psychopharmacology (Berl); 1976 Dec; 51(1):15-22. PubMed ID: 13446
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
17. Animal models for tardive dyskinesia: effects of thioridazine.
Sayers AC; Bürki HR; Ruch W; Asper H
Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):291-5. PubMed ID: 616929
[TBL] [Abstract][Full Text] [Related]
18. Neuronal basis of neuroleptic-induced extrapyramidal side effects.
Ossowska K
Pol J Pharmacol; 2002; 54(4):299-312. PubMed ID: 12523484
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs.
Lidow MS; Goldman-Rakic PS
J Pharmacol Exp Ther; 1997 Nov; 283(2):939-46. PubMed ID: 9353417
[TBL] [Abstract][Full Text] [Related]
20. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
Jeste DV; Wyatt RJ
J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
